Galunisertib Combined With Capecitabine in Advanced CRC With PM

Status Not yet recruiting

Clinical Trial Summary

This is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of capecitabine and galunisertib in patients with colorectal cancer with peritoneal metastases.

Clinical Trial Description

This is a two-center pharmacological open-label non-randomized proof of principle study consisting of two parts: a phase I study evaluating the RP2D of galunisertib in combination with capecitabine; and a phase II study investigating the anti-tumor activity and safety of galunisertib in combination with capecitabine in advanced colorectal cancer (CRC) with peritoneal metastases (PM). In phase II of the study a Simon two-stage design will be used. 15 patients will be treated with the galunisertib/capecitabine combination. If at least 2 out of 15 patients respond, an additional cohort of 10 patients will be included to a total of 25 patients. With 6 or more responses, the treatment will be declared to be of sufficient activity and with 5 or less it will be declared of insufficient activity. The galunisertib dose will be 150 mg twice daily (BID) for the first 14 days of every 4-week cycle, which is the maximum tolerated dose when given as single agent (except of day 1 of cycle 1: single dose of galunisertib 150 mg for PK analysis, from day 2: 150 mg BID). Capecitabine will be dosed during every 14-day on time of galunisertib at 1000 mg/m2 BID, which is the labelled dose as monotherapy and will in case of toxicities be reduced according to standard care. Clinical assessments will be performed routinely to monitor safety. Anti-tumor activity will be measured by CT scan according to RECIST 1.1 criteria. Tumor biopsies will be obtained for exploratory objectives. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05700656
Study type	Interventional
Source	The Netherlands Cancer Institute
Contact	Alaa Embaby, MD
Phone	0031205129111
Email	a.embaby@nki.nl
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	April 2023
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03941080` - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed	`NCT03213314` - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies	N/A
Completed	`NCT03647839` - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer	Phase 2
Recruiting	`NCT05057052` - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis	Phase 2
Terminated	`NCT02316496` - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study	Phase 2
Completed	`NCT03251612` - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer	Phase 2
Completed	`NCT02380443` - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT02149784` - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients	Phase 3
Recruiting	`NCT01959061` - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases	Phase 4
Terminated	`NCT01668680` - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma	Phase 2
Recruiting	`NCT05068531` - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting	`NCT04525807` - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed	`NCT04482608` - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting	`NCT03193710` - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved	N/A
Recruiting	`NCT04854213` - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)	N/A
Suspended	`NCT04108481` - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT03142516` - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status	Phase 2
Completed	`NCT03144804` - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer	Phase 2
Active, not recruiting	`NCT01910610` - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer	Phase 3
Recruiting	`NCT05759728` - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer	Phase 1/Phase 2